Evidence map›Paper›PMID 35735430›Full record

ArticleCurrent oncology (Toronto, Ont.)2022

Promising Therapeutic Impact of a Selective Estrogen Receptor Downregulator, Fulvestrant, as Demonstrated In Vitro upon Low-Grade Serous Ovarian Carcinoma Cell Lines.

Kamrunnahar Shanta, Kentaro Nakayama, Mohammad Mahmud Hossain, Sultana Razia, Tomoka Ishibashi, Masako Ishikawa, Hitomi Yamashita, Kosuke Kanno, Seiya Sato, Satoru Nakayama and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Kamrunnahar ShantaDepartment of Obstetrics and Gynecology, Faculty of Medicine, Shimane University, Izumo 693-8501, Japan.ORCID 0000-0002-4221-204X
Kentaro NakayamaDepartment of Obstetrics and Gynecology, Faculty of Medicine, Shimane University, Izumo 693-8501, Japan.
Mohammad Mahmud HossainDepartment of Obstetrics and Gynecology, Faculty of Medicine, Shimane University, Izumo 693-8501, Japan.ORCID 0000-0001-8806-1788
Sultana RaziaDepartment of Obstetrics and Gynecology, Faculty of Medicine, Shimane University, Izumo 693-8501, Japan.
Tomoka IshibashiDepartment of Obstetrics and Gynecology, Faculty of Medicine, Shimane University, Izumo 693-8501, Japan.
Masako IshikawaDepartment of Obstetrics and Gynecology, Faculty of Medicine, Shimane University, Izumo 693-8501, Japan.
Hitomi YamashitaDepartment of Obstetrics and Gynecology, Faculty of Medicine, Shimane University, Izumo 693-8501, Japan.
Kosuke KannoDepartment of Obstetrics and Gynecology, Faculty of Medicine, Shimane University, Izumo 693-8501, Japan.
Seiya SatoDepartment of Obstetrics and Gynecology, Faculty of Medicine, Shimane University, Izumo 693-8501, Japan.
Satoru NakayamaDepartment of Obstetrics and Gynecology, Seirei Hamamatsu Hospital, Hamamatsu 430-8558, Japan.
Yoshiro OtsukiDepartment of Organ Pathology, Seirei Hamamatsu Hospital, Hamamatsu 430-8558, Japan.ORCID 0000-0002-0568-3811
Satoru KyoDepartment of Obstetrics and Gynecology, Faculty of Medicine, Shimane University, Izumo 693-8501, Japan.ORCID 0000-0002-8986-6147
Shimane University · JPSeirei Hamamatsu General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Few studies have reported hormonal agent use in the treatment of low-grade serous ovarian carcinomas (LGSOCs), which are chemoresistant. Considering the need for novel effective therapies, we investigated the hormone receptor expression and hormonal inhibition efficacy in LGSOCs. Using immunohistochemistry, we assessed the estrogen receptor (ER) expression status in 33 cases of histologically confirmed serous ovarian tumors, including 10, 11, and 12 cases of LGSOCs, serous borderline tumors (SBTs), and serous cystadenomas (SCAs), respectively. The genetic background reported in our previous study was used in the current study. MPSC1 cells, which were established from LGSOCs, were used in cell proliferation assays. We observed a higher ER expression in LGSOCs and SBTs than in SCAs (70%, 81%, and 50%, respectively). Thus, LGSOCs and SBTs exhibit higher ER expression than SCAs. Moreover, the

Indexed as

Cystadenocarcinoma, SerousOvarian NeoplasmsPeritoneal NeoplasmsCell LineFemaleFulvestrantHumansPhosphatidylinositol 3-KinasesReceptors, EstrogenFulvestrantPhosphatidylinositol 3-KinasesReceptors, Estrogenestrogen receptorfulvestrantlow-grade serous ovarian carcinomaPIK3CA

Identifiers

PMID35735430
PMCPMC9221871
OpenAlexW4281673889

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.